Sourasky Medical Center (Ichilov)
| イスラエル | トルコ | オーストリア | |
| 幹細胞治療 | - | から $15,000 | から $40,000 |
Dr. Nir Giladi leads the Neurology Unit at Sourasky Medical Center in Israel. He is a primary investigator for Parkinson’s research with the Michael J. Fox Foundation. Dr. Giladi specializes in movement disorders, parkinsonism, and extrapyramidal conditions. He completed his fellowship at Columbia University in the United States.
Israel approved Leqembi (lecanemab) in July 2024 and Kisunla (donanemab) in late 2024 for early-stage Alzheimer's. These monoclonal antibodies target amyloid plaques to slow cognitive decline. Patients receive these therapies via intravenous infusion at major centers like Sourasky Medical Center and Rambam Medical Center.
Bookimed Expert Insight: While these medications are approved, they are not currently in the national health basket. Our data shows patients often choose JCI-accredited centers like Sourasky or Assuta for private administration. These facilities offer access to specialists like Dr. Tatyana Gurevich and Prof. Nir Giladi, who manage the complex monitoring required for these new biological therapies.
Patient Consensus: Patients note that while approvals are exciting, high out-of-pocket costs remain a major hurdle. Many suggest checking clinical trial eligibility at large hospitals to access these treatments faster and more affordably.
Israel's National Health Basket covers essential Alzheimer's diagnostic services, specialist consultations, and first-line medications for mild-to-moderate stages. Established drug families like acetylcholinesterase inhibitors are included. However, newer biological treatments like Leqembi and specialized medical technologies currently remain excluded from public funding for 2026.
Bookimed Expert Insight: Israeli medical centers like Sourasky and Hadassah are global hubs for neurological research, often providing access to treatments not yet in the health basket. For example, Dr. Itzhak Fried at Sourasky and Prof. Tamir Ben-Hur at Hadassah lead studies on surgical interventions and stem cell therapies. Patients often seek these academic centers to participate in clinical trials, which can provide access to restricted biological drugs without the significant out-of-pocket costs typically required for private prescriptions.
Patient Consensus: Patients note that while basic medications are accessible, the public approval process for specific drugs can vary significantly between different health funds. Many emphasize the need to budget for non-covered supplements and recommend starting the formal diagnosis early to avoid delays in receiving subsidized care.
Patients secure an Alzheimer's diagnosis in Israel through a tiered clinical pathway. The process begins with a primary care screening. Specialists at JCI-accredited centers like Sourasky Medical Center or Hadassah then perform advanced neuroimaging and cognitive assessments. Definitive diagnosis often requires MRI, PET scans, or lumbar punctures.
Bookimed Expert Insight: Data suggests focusing on multidisciplinary centers like Sourasky Medical Center in Tel Aviv. This facility operates 240 departments and processes 1,800,000 patients annually. Choosing such large-scale institutions often provides faster access to integrated teams of neurologists and neurosurgeons. For example, Prof. Itzhak Fried at Sourasky specializes specifically in senile dementia of the Alzheimer's type. This targeted expertise is more common in high-volume academic hospitals than in smaller private clinics.
Patient Consensus: Patients note that public waitlists for full neurological evaluations can take 3 to 6 months. Many suggest presenting functional decline as urgent to speed up the process for essential nursing care subsidies.
Israel offers extensive non-pharmacological support for Alzheimer’s patients through specialized medical centers and community programs. These services include cognitive rehabilitation, sensory therapies, and structured day care. Facilities like Sourasky Medical Center and Hadassah Medical Center provide multidisciplinary neurological care and innovative behavioral protocols.
Bookimed Expert Insight: Israeli medical centers like Sourasky and Hadassah are unique because their neurological departments are led by professors who also conduct global clinical research. For example, Dr. Nir Giladi and Dr. Itzhak Fried combine active surgical practice with memory disorder research. This means patients often access the latest behavioral protocols months before they become standard global practice.
Patient Consensus: Patients emphasize that joining support groups through the Alzheimer's Israel association helps manage agitation. Families frequently recommend local day centers to provide social stimulation and essential respite for primary caregivers.
International patients can participate in clinical trials in Israel for Alzheimer's disease. Approval from the Ministry of Health and a Helsinki Committee is mandatory for all studies. Major centers like Sourasky and Hadassah actively recruit participants for innovative stem cell and neuroimmunology research.
Bookimed Expert Insight: Sourasky Medical Center serves over 1,800,000 patients annually and houses specialized units for functional neurosurgery. Professors like Dr. Nir Giladi and Dr. Itzhak Fried lead research with over 300 combined publications. Patients should target these high-volume academic centers as they often pioneer global protocols for memory recovery.
Patient Consensus: Patients emphasize completing virtual pre-screening through hospital portals to avoid rejection after traveling. Many note that while the medical treatment is free, budgeting for a 3-month bureaucratic process is essential.
Leqembi (Lecanemab) is approved for treating Alzheimer's disease in Israel as of July 2024. The drug is authorized for adults in early stages with mild cognitive impairment. Israeli medical centres, including Sourasky (Ichilov), were among the first globally to administer the treatment.
Bookimed Expert Insight: Sourasky Medical Center serves over 1,800,000 patients annually and holds JCI accreditation for safety. This high volume and international standing helped it secure early access to Lecanemab. Patients usually need amyloid confirmation via PET scans or spinal fluid tests before starting this therapy.
Patient Consensus: Patients in Israel note that while approval is a milestone, it typically slows decline rather than reversing it. They emphasize that the intensive work-up, including mandatory MRI monitoring and genetic risk assessments, requires significant time and effort.
Alzheimer's treatment in Israeli hospitals focuses on symptomatic management and advanced disease-modifying therapies. Specialists use cholinesterase inhibitors and NMDA receptor antagonists for cognitive support. Leading facilities like Tel Aviv Sourasky Medical Center provide newer monoclonal antibody infusions, such as Lecanemab, to target amyloid plaques.
Bookimed Expert Insight: Israeli neurology units often combine university-led research with clinical practice. Professor Itzhak Fried at Sourasky Medical Center also teaches at UCLA. This ensures patients receive care that meets both Middle Eastern and elite American clinical standards. This dual-affiliation is a key quality signal for those seeking the latest international protocols.
Patient Consensus: Patients note that Israeli hospital stays usually address acute issues like delirium or infections rather than just routine monitoring. Families find that staying involved to explain a patient's normal baseline helps staff adjust medications and manage confusion effectively.
Leading Israeli medical centres for Alzheimer's include Sourasky Medical Center, Sheba Medical Center, and Hadassah Medical Center. These JCI-accredited facilities offer advanced memory clinics. They specialise in early diagnostics, clinical trials for breakthrough drugs like Lecanemab, and non-invasive neuromodulation therapies within integrated neurology departments.
Bookimed Expert Insight: While major hospitals like Hadassah and Sourasky serve over 1,000,000 patients annually, their Alzheimer's care is highly personalised. Data shows these academic centres often lead international clinical trials. This gives patients access to emerging pharmacological treatments years before they reach the general market in Australia.
Patient Consensus: Patients note that major tertiary hospitals in Israel are the best choice for complex cognitive cases. They highlight that English-speaking coordination and a multidisciplinary team approach are vital for international families managing long-distance care.
Israeli researchers lead breakthroughs in Alzheimer's treatment by focusing on brain repair and immune system modulation. Key developments include CAR T-cell therapy to clear amyloid proteins and nanoparticles that reactivate brain cleaning pathways. These shifts aim to reverse cognitive damage rather than just managing symptoms.
Bookimed Expert Insight: Israeli research uniquely bridges the gap between laboratory discovery and clinic. Facilities like Sourasky Medical Center and Hadassah Medical Center serve over 1,000,000 patients annually because they integrate university-led research directly into hospital departments. For Australians, this means access to specialists like Prof. Tamir Ben-Hur, who balances regenerative medicine research with active clinical neurology.
Patient Consensus: Israel is a primary hub for moving lab findings into human trials, focusing on multi-target approaches like tau proteins and metabolic dysfunction. Patients note that most breakthroughs target early-stage disease, requiring blood-based biomarkers or neuroimaging for trial matching.
Israeli medical centres provide extensive logistical support through dedicated international departments. Families access personal case managers, help with medical visas, and multilingual staff at JCI-accredited facilities. These services cover airport transfers, local accommodation, and telemedicine follow-ups. Support ensures families focus entirely on the patient's care.
Bookimed Expert Insight: Israeli hospitals like Hadassah and Sourasky operate as massive medical hubs, treating up to 1,000,000 patients annually. Because of this high volume, their international departments are exceptionally efficient at navigating bureaucracy. Choosing a centre with deep research ties, like the university-affiliated Hadassah, often provides better access to travel-ready digital imaging and integrated pharmacy support.
Patient Consensus: Patients in Israel recommend pre-booking private airport transfers and wheelchair assistance for much smoother arrivals. Having one family member dedicated solely to managing paperwork and digital scan copies helps prevent common administrative delays.